-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Candel Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q2 2020 to Q2 2024.
- Candel Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending June 30, 2024 was -$13.7M, a 38946% decline year-over-year.
- Candel Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was -$14.3M, a 457% decline year-over-year.
- Candel Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was $452K, a 97.2% decline from 2022.
- Candel Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was $15.9M.
- Candel Therapeutics, Inc. annual Nonoperating Income (Expense) for 2021 was -$10.4M, a 169% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)